Geron Corporation
GERNHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeGeron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. Valued at $911.0M, GERN is a small-cap name in its sector. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML.
Market Cap
$911.0M
Beta
0.60
P/E (TTM)
—
P/E (Fwd)
23.67
EPS (TTM)
$-0.11
EPS (Fwd)
$0.06
ROE
-27.1%
ROA
-4.0%
Cash
$312.4M
Total Debt
$122.1M
Free CF
-$92.1M
52W Change
10.1%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $312.4M in cash comfortably exceeding the $122.1M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$92.1M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -27.1% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $596K (2022) to $183.9M (2025), reflecting a 30753% increase over the period.
The relatively low beta of 0.60 suggests GERN is a less volatile holding compared to the broader index. With cash comfortably exceeding debt, GERN has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing GERN's risk profile alongside its fundamentals and technical indicators provides a more complete picture.